BLD-2660 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
85	Idiopathic interstitial pneumonia	2

85. Idiopathic interstitial pneumonia

---

Clinical trials : 598 /  Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-004998-34-GB (EUCTR)	16/07/2020	04/02/2020	A clinical study to investigate the safety and effects of a new drug called BLD-2660 in patients with Idiopathic Pulmonary Fibrosis	A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic Pulmonary Fibrosis - B-2660-203	Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Product Name: BLD-2660 Product Code: BLD-2660 INN or Proposed INN: None Other descriptive name: BLD-2660	Blade Therapeutics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	40	Phase 2	United Kingdom
2	NCT04244825 (ClinicalTrials.gov)	December 15, 2019	3/1/2020	Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF	A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: BLD-2660;Drug: Control: Placebo	Blade Therapeutics	NULL	Withdrawn	45 Years	N/A	All	0	Phase 2	United Kingdom